Individual Patient Based Meta-analysis of Lentinanfor Unresectable/Recurrent Gastric Cancer
Background: In the present study, the effect ofimmunochemotherapy with lentinan compared with that ofchemotherapy alone was evaluated in patients with advancedgastric cancer through individual patient data (IPD) metaanalysis.
Materials and Methods: Based on a computerizedand manual search, all eligible centrally randomizedcontrolled trials (RCT) which compared chemotherapyregimens with or without lentinan administration foradvanced gastric cancer patients were included.
Results: Intotal, 650 IPD from 5 trials were available. Lentinansignificantly prolonged the overall survival (stratified logrankp=0.011). The overall hazard ratio (HR) was 0.80(95% confidence interval=0.68-0.95) and there was noheterogeneity between trials. Additionally, lentinan waspossibly more effective in patients with lymph-nodemetastasis than in non-node metastasis patients (P forinteraction=0.077).
Conclusion: The addition of lentinan tostandard chemotherapy offers a significant advantage overchemotherapy alone in terms of survival for patients withadvanced gastric cancer.
【下载地址】Individual Patient Based Meta-analysis of Lentinanfor UnresectableRecurrent Gastric Cancer.pdf
编辑: zhouj
以下网友留言只代表网友个人观点，不代表网站观点
|
